Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Its biomarkers include CRP/C-reactive protein, procalcitonin, Nt-pro-BNP, lipids, HbA1c/D-vit… Read more
Qlife Holding AB (QLIFE) - Total Liabilities
Latest total liabilities as of December 2025: Skr17.14 Million SEK
Based on the latest financial reports, Qlife Holding AB (QLIFE) has total liabilities worth Skr17.14 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Qlife Holding AB - Total Liabilities Trend (2019–2025)
This chart illustrates how Qlife Holding AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Qlife Holding AB Competitors by Total Liabilities
The table below lists competitors of Qlife Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Txcom SA
PA:ALTXC
|
France | €2.33 Million |
|
Lilium Equity Warrants
PINK:LILMW
|
USA | $280.49 Million |
|
VS Media Holdings Limited Class A Ordinary Shares
NASDAQ:VSME
|
USA | $709.83K |
|
Autocorp Holding Public Company Limited
BK:ACG
|
Thailand | ฿444.81 Million |
|
Prolexus Bhd
KLSE:8966
|
Malaysia | RM68.30 Million |
|
Discovery Lithium Inc.
PINK:DCLIF
|
USA | $1.36 Million |
|
Cinevista Limited
NSE:CINEVISTA
|
India | ₹908.97 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Qlife Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qlife Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qlife Holding AB (2019–2025)
The table below shows the annual total liabilities of Qlife Holding AB from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr17.14 Million | +31.18% |
| 2024-12-31 | Skr13.07 Million | -78.98% |
| 2023-12-31 | Skr62.17 Million | -38.75% |
| 2022-12-31 | Skr101.50 Million | +235.47% |
| 2021-12-31 | Skr30.26 Million | -19.62% |
| 2020-12-31 | Skr37.64 Million | +166.61% |
| 2019-12-31 | Skr14.12 Million | -- |